Leadership

Rajiv Malik is Mylan's Executive Vice President and Chief Operating Officer. Previously, he served as Executive Vice President in charge of Global Technical Operations. Malik served in a similar capacity for Mylan since January 2007, when Mylan acquired a controlling stake in Matrix Laboratories Limited, one of the world's largest suppliers of active pharmaceutical ingredients.

As Chief Operating Officer, Malik will continue to be responsible for areas he supervised as Head of Global Technical Operations, including Mylan's global research and development (R&D) centers, and manufacturing and distribution units. He also will oversee the company's generic biologics efforts as well as those initiatives related to emerging markets. In addition, Malik is responsible for enhancing and rationalizing Mylan's global supply chain and expanded product pipeline, as well as leveraging Matrix's capabilities across the company.

Malik has worked for more than 24 years in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was Head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to Head of Generics R&D.

Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

S. Srinivasan
CEO and Managing Director

S. Srinivasan is the CEO and managing director of Matrix, a position he has held since January 2009. In a 15-year career at Matrix, Srinivasan has distinguished himself in a wide range of functional areas, including finance, sales and marketing, business development and strategic planning. He has made significant contributions to the expansion of the company’s businesses regarding active pharmaceutical ingredients and antiretrovirals.

Previously, Srinivasan has served as Matrix’s chief operating officer. Before that, he was the company’s senior vice president of Strategic Business Planning and Global Alliances. Srinivasan earned a bachelor’s degree in engineering from Madurai Kamaraj University, India, and a Master of Business Administration from the Institute of Rural Management Anand, India. In addition, he is a management accountant certified by the Institute of Cost & Works Accountants of India.

Dr. B. Hari Babu holds a master’s degree and a Ph.D. in organic chemistry from Andhra University.

He started his professional career in research and development, followed by working in regulatory affairs, quality assurance and production at various active pharmaceutical ingredients companies.

Dr. B. Hari Babu is currently the chief operating officer and executive director of Matrix and has assisted the company in becoming a world-class manufacturer in the pharmaceutical industry. He also has played an active role in getting significant approvals/accreditations for Matrix from the U.S. Food and Drug Administration, Australia’s Therapeutic Goods Administration and International Organization for Standardization 9000 .

He has more than 17 years of experience in the pharmaceutical industry.

Sanjeev Sethi has a Masters in Pharmaceutical Sciences from Punjab University, Chandigarh. He has 20 years experience in the pharmaceutical industry, in leading companies such as Ranbaxy, Delhi (formulations development and International Regulatory Affairs ) and Sandoz, Vienna (Deputy. Head, Research and Development).

Mr. Sethi is currently Sr Vice President – Global Generics R&D, Mylan. Prior to this role, he held the position of executive vice president of Finished Dosage Forms and Technical Operations at Matrix.

He has to his credit 40 international patents.